John C. King
Corporate Officer/Principal bei VOR BIOPHARMA INC.
Profil
John C.
King is currently the Chief Commercial Officer at Vor Biopharma, Inc. He previously worked as the Vice President of the US Neurology Business Unit at Alexion Pharmaceuticals, Inc. from 2017 to 2018, and as the Chief Commercial Officer at Ra Pharmaceuticals, Inc. from 2018 to 2020.
Prior to that, he worked as a Product Director for Enbrel at Wyeth Pharmaceuticals LLC.
Mr. King received his undergraduate degree and MBA from The Pennsylvania State University.
Aktive Positionen von John C. King
| Unternehmen | Position | Beginn |
|---|---|---|
| VOR BIOPHARMA INC. | Corporate Officer/Principal | 01.08.2020 |
Ehemalige bekannte Positionen von John C. King
| Unternehmen | Position | Ende |
|---|---|---|
| RA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.08.2020 |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.03.2018 |
Wyeth Pharmaceuticals LLC
 Wyeth Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA. | Corporate Officer/Principal | - |
Ausbildung von John C. King
| The Pennsylvania State University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| VOR BIOPHARMA INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Ra Pharmaceuticals, Inc.
 Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of peptide-based drugs. It uses Extreme Diversity platform that allows to produce synthetic macrocyclic peptides. The company was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Wyeth Pharmaceuticals LLC
Wyeth Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA. | Health Technology |
